|
In a
letter to the conglomerate, Fujifilm cited media reports saying
profits from the sale would contribute to Toshiba's finances in
the fiscal year through March, and questioned whether the deal
would close in time for that. Fujifilm disclosed the contents of
the letter to the media.
The move is a rare challenge by a failed bidder in Japan.
Fujifilm demanded a reply to the letter by 0600 GMT on Thursday.
Toshiba declined on Wednesday to comment on the letter,
including whether it will respond to it.
Fujifilm said regulatory approvals normally took at least a
month to process based on anti-monopoly laws, meaning any sale
of the unit, called Toshiba Medical, was unlikely to conclude by
the end of March.
"The United States, Europe, China and others have M&A
regulations similar to Japan's anti-monopoly laws... We would
like to know Toshiba's understanding on this question, and
whether it has arranged special measures for this," the letter
said.
Toshiba last week granted Canon exclusive negotiating rights to
buy unlisted Toshiba Medical after a hotly contested auction.
One source with knowledge of the talks put Canon's offer at more
than $6 billion, which would help bolster Toshiba's capital in
the wake of last year's accounting scandal.
(Reporting by Makiko Yamazaki; Writing by Ritsuko Ando; Editing
by Muralikumar Anantharaman)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
